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Abstract Background: The early years of life have a profound effect on a child’s devel-
opmental pathway. The children born to mothers suffering from depression
may be at risk of increased morbidity and mortality in the first years of life.
Objective: The objective of this study was to investigate the hospital admis-
sions and mortality of children whose mothers were dispensed a selective
serotonin reuptake inhibitor (SSRI) during their pregnancy.
Methods: This was a population-based study of all pregnancy events in
Western Australia (WA) from 2002 to 2005. The study used linkable state
health administrative data from the WA Data Linkage System (WADLS)
and the national Pharmaceutical Benefits Scheme (PBS), enabling birth out-
comes, hospital admissions and deaths to be ascertained for the children of
women dispensed an SSRI during their pregnancy.
Results: There were 3764 children born to 3703 women who had been dis-
pensed an SSRI during their pregnancy (3.8% of all pregnancies in WA,
2002–5), and 94 561 children born to 92 995 women who had not been dis-
pensed an SSRI. Mean birth weight, length and APGAR score at 5 minutes
were significantly lower in children of women dispensed an SSRI, regardless
of whether the SSRI was dispensed in trimester 1, or, trimester 2 or 3 only.
0.9% of the live born children in the SSRI group had died before the age of
1 year compared with 0.5% of the non-SSRI group (odds ratio [OR] 1.8; 95%
CI 1.3, 2.6). Before the age of 2 years, 42.9% of the children in the SSRI group
had been admitted to hospital after their birth admission, compared with
34.1% of the non-SSRI group (OR 1.4; 95% CI 1.3, 1.6). The most common
reason for admission to hospital was acute bronchiolitis (OR 1.6; 95% CI 1.3,
1.8), with an increased risk seen in children of mothers who did not smoke
during their pregnancy (OR 1.7; 95% CI 1.4, 2.0).
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Conclusions: The children in the SSRI group were more likely to be ad-
mitted to hospital in the first years of life, and this may reflect their pre-
natal exposure to SSRIs, be related to maternal depression, or SSRI use
may be a proxy for an environmental exposure such as smoking, or a com-
bination of these factors. Although the numbers of deaths in the first year
of life were small, the increased risk of death in the first year of life in the
SSRI group (OR 1.8; 95% CI 1.3, 2.6) is a new finding and should be in-
vestigated further.
Background
The highest rates for depression occur in women
between the ages of 25 and 44 years,[1] and these
years account for the majority of the child-bearing
period. The largest, and most recent, survey of
pregnant women in Australia found approxi-
mately 9% of the women surveyed fulfilled the
diagnostic criteria for depression.[2] A study of
women with a prior history of major depression
found that those who discontinued antidepressant
treatment were five times more likely to relapse
during pregnancy than those who continued treat-
ment during pregnancy.[3] The part played by the
underlying depression in the mother in relation to
neonatal outcomes is not clear. Studies by Field
et al.[4,5] considered relationships between pre-
natal depression and decreased foetal growth and
between cortisol and shorter gestation but did not
distinguish between mothers taking antidepres-
sants and those that did not.
Selective serotonin reuptake inhibitors (SSRIs)
are used in the treatment of depression and in
anxiety disorders such as panic disorder, as well
as chronic pain. Studies have shown that SSRIs
readily cross the placenta,[6] are present in am-
niotic fluid[7] and newborns exposed to them
in utero may experience withdrawal behaviours
after birth.[8,9] A review by Belik[10] found the
available information related to the clinical symp-
toms of infants exposed to SSRIs in utero is limited
to small cohort studies, case reports and to inter-
national collaborative programmes that monitor
adverse reactions to drugs, such as the USA FDA
and the WHO Collaborating Centre for Interna-
tional Drug Monitoring. There have been some
follow-up studies of the children exposed to SSRIs
in utero. A review of neurodevelopmental out-
comes by Gentile and Galbally[11] found there
were very few longitudinal studies of children
exposed in utero to antidepressants. Another review
of late pregnancy exposure to antidepressants
found a constellation of recurrent symptoms in
the first days of life in the newborns and sug-
gested that the term ‘prenatal antidepressant-
exposure syndrome’ be used to describe it.[12]
Early hospital admissions, particularly after
the birth admission, in children exposed to SSRIs
in utero have not been investigated. We have pre-
viously reported the dispensing patterns, preg-
nancy and birth outcomes of women dispensed
an SSRI during their pregnancy in a population-
based study relating to all pregnancy events in
Western Australia (WA) from 2002 to 2005 (N =
96 968 pregnancies resulting in a birth).[13] There
were 3703 women (3764 children) dispensed an
SSRI during their pregnancy. 42.3% of these
women were dispensed an SSRI in each trimester,
75.4% of the women were dispensed an SSRI in
consecutive trimesters and 97.6% of the women
used the same SSRI throughout the first trimester
without switching. However, we did not report
the effects of SSRI by trimester of exposure, nor
outcomes for the child beyond birth.
Objectives
Using data linkage of population-based data,
we investigated the early hospital admissions and
mortality for the children of the women described
in our previous paper[13] and compared hospital-
isation and mortality rates of these children with
rates for all other children whose mothers were
not dispensed an SSRI.
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Methods
Study Design
This was a population-based study relating to
all pregnancy events in WA from 2002 to 2005.
The study used linkable state health adminis-
trative data from the WA Data Linkage System
(WADLS, which contains data from the Hospital
Morbidity Data System, the Midwives’ Notifi-
cation System, the WA Registry of Births and
Deaths and the WA Register of Developmental
Anomalies) and the national Pharmaceutical Ben-
efits Scheme (PBS), enabling birth outcomes, hos-
pital admissions and deaths to be ascertained for
the children of those women dispensed an SSRI
during their pregnancy. The PBS is a claims data-
base that includes 80% of all prescriptions dis-
pensed in Australia. The linkages andmethodology
have been described previously.[13-15]
Setting
During 2002–5 there were six generic medicines
listed on the PBS that fell under the category
of SSRI (citalopram hydrobromide, escitalopram
oxalate, fluoxetine hydrochloride, fluvoxamine
maleate, paroxetine hydrochloride and sertraline
hydrochloride). SSRIs are only available inAustralia
on the PBS as a ‘Restricted Benefit’ for major de-
pressive disorders, obsessive-compulsive disorder
(fluoxetine, fluvoxamine, paroxetine, sertraline)
or panic disorder (paroxetine, sertraline)[16] and
are not available over the counter.
The International Statistical Classification of
Diseases and Related Health Problems, Tenth
Revision, Australian Modification (ICD-10-AM)/
Australian Classification of Health Interventions
(ACHI) is the system used to code inpatient epi-
sodes of care in all Australian public and private
hospitals. The ICD-10-AM is used to code
diseases and problems.[17]
Participants
As hospital admission data were available
from 2002 to 2006, admissions were analysed for
all children to the age of 1 year, and to 2 years for
those children born 2002–4. Characteristics of
the mothers and children are from the midwives’
records.
Major Variables and Data Sources Used in
Outcome Measurements
The hospital admission data include a principal
diagnosis and up to 20 additional diagnoses as re-
corded on the discharge records. The codes are
based upon ICD-10-AM.[17] According to the Hos-
pital Morbidity Data System coding guide that was
current during the study,[18] additional diagnoses
with the following characteristics need to be coded:
 require therapeutic treatment;
 require performance of a diagnostic procedure;
 increase nursing care and/or monitoring; or,
 may extend the length of stay in hospital.
The admission data were validated and re-
cords were merged if the child was re-admitted
within a day for the same principal diagnosis, to
the third ICD-10-AMdigit. This will also reflect a
more clinical view of admissions as hospital
transfers will be recognized as the same episode of
care and counted as one admission. Lengths of
stay (LOS) were calculated as the number of days
from admission to discharge for the same episode
of care. Admissions discharged on the same day
were allocated a LOS of 0.5 day.
The Midwives’ Notification System was used
to determine stillbirths. The WA Registry of
Deaths provided the date of death for all deaths.
The Australian Bureau of Statistics has released
Socio-Economic Indexes for Areas (SEIFA) based
on the information collected in the 5-yearly Census
of Population and Housing. These indexes are
widely used measures of relative socio-economic
status at a small geographical area level. The in-
dexes rank and identify areas that are relatively
more, or less, disadvantaged. They provide con-
textual information about the area in which a
person lives. The indexes have been obtained by a
principal components analysis that summarizes
the information from a variety of social and
economic variables, calculating weights that will
give the best summary for the underlying vari-
ables. The categories of variables include income,
education, employment, occupation and housing.
The mean rank is 1000.[19] The SEIFA values
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in this study are based upon the 2001 Australian
Census of Population and Housing.
The variable, Proportion of Optimal Birth
Weight (POBW), was calculated as a measure of
the appropriateness of foetal growth.[20] POBW
is independent of gestational age and takes into
account the major non-pathological determi-
nants of intrauterine growth. POBW is the ratio
of the observed to the ‘optimal’ birth weight; the
latter estimated from a regression equation in-
cluding terms for gestational duration, maternal
height, parity and infant sex, derived from a total
population of singleton births that excluded those
exposed to risk factors for intrauterine growth
restriction, including maternal smoking.[21]
Statistical Methods
Comparisons were made between the children
of women dispensed an SSRI at any time during
pregnancy and those not dispensed an SSRI at
any time during their pregnancy. ORs with 95%
confidence intervals were calculated to assess the
strength of association of the child character-
istics, admission rates and LOS. Stepwise logistic
regression using the SAS (SAS Institute Inc.,
Cary, NC, USA) procedure, PROC LOGISTIC,
was used to adjust ORs. T-tests were used to com-
pare means where appropriate. Some compar-
isons were made using just the term births to
avoid the potential effects of preterm birth. The
infant mortality rate (deaths to age 1 year in live
births) in Australia for the period 2000–5 was
4.959 per 1000 live births.[22] There were 3738 live
births in the SSRI group. Our study had 88%
power to detect 9 per 1000 live births.[23]
The WADLS uses the Automatch software
package (Matchware Technologies Inc., Kenne-
bunk,ME,USA) with probabilistic matching based
upon medical record number, surname, first given
name and initial, date of birth, sex and address as
the principal matching fields. Missed links have
been estimated at 0.11%.[24] The WADLS has
been validated previously[24,25] and has been used
extensively for health research.[26] All records for
this study were also validated internally. For ex-
ample, sex and dates of birth or death were
checked across each source. The datasets were
analysed using SAS/STAT software, version
9.2 of the SAS System forWindows (SAS Institute
Inc., Cary, NC, USA). The researchers received all
data in a de-identified form from the WADLS.
Ethics Approvals
This project has approval from the Human
Research Ethics Committees of The University of
WA and the WA Department of Health.
Results
From 2002 to 2005 in WA there were 96 698
pregnancies resulting in the birth of 98 325 infants.
There were 16 294 dispenses of an SSRI.
Characteristics of the Children and Their Birth
Outcomes, by Trimester of Exposure
There were 3764 children born to 3703 (3.8%
of all pregnancies in WA, 2002–5) women who
had been dispensed an SSRI during their preg-
nancy, and 94 561 children born to 92 995 women
who had not been dispensed an SSRI during
pregnancy. The characteristics of the women and
children are reported in table I showing the dif-
ferences between women dispensed an SSRI in
trimester 1 (T1, N = 2654), or those dispensed an
SSRI in trimester 2 or 3 only (T2 or T3, N =
1049), and all other women. The mean number
of dispenses per pregnancy was 2.2 in T1 and 4.4
for any time in pregnancy. An APGAR score at
5 minutes of less than 6 was more likely in chil-
dren of women dispensed an SSRI in T1 (OR 1.8;
95% CI 1.4, 2.3) than those dispensed only in T2
or T3 (OR 1.2; 95% CI 0.8, 2.0) when compared
with the children in the non-SSRI group. Preterm
birth was also more likely in the T1 group (ad-
justed OR 1.6; 95% CI 1.3, 1.9) than those in T2
or T3 only (adjusted OR 1.3; 95%CI 1.0, 1.7), after
adjusting for a previous preterm birth, smoking,
SEIFA, parity and maternal age, and considering
only singletons. When the risk of a birth weight
<2500 g was adjusted for gestational age, whether
the mother smoked during her pregnancy, SEIFA,
sex, parity and maternal height, dispenses in T2
or T3 only remained significant (adjusted OR 1.5;
95% CI 1.1, 2.0).
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Death in the First Year of Life
For the live born children, 0.9% of the children
in the SSRI group had died before the age of 1 year
compared with 0.5% of the children in the non-
SSRI group (OR 1.8; 95% CI 1.3, 2.6) [table II].
The mean age at death in the first year was 7.2
weeks for the children in the SSRI group and 5.9
weeks for the children in the non-SSRI group.
There was no increased risk of stillbirth (OR
Table II. Deaths before 1 year of age for children born to women dispensed a selective serotonin reuptake inhibitor during pregnancy, 2002–5
Outcome SSRIs N =3764 Non-SSRIs N =94 561









Death before 1 year 58 1.5 30.4 1058 1.1 29.1 1.38 (1.06, 1.81)
Citalopram 14 1.2 28.8 1.08 (0.64, 1.84)
Paroxetine 11 1.6 32.2 1.44 (0.79, 2.63)
Sertraline 22 1.6 30.7 1.45 (0.95, 2.22)
Fluoxetine 6 1.6 30.2 1.45 (0.65, 3.26)
Escitalopram 5 2.0 31.6 1.85 (0.76, 4.49)
Fluvoxamine < 5 2.1 37.5 1.89 (0.60, 5.95)
Stillbirthsa 26 0.7 29.8 612 0.6 27.6 1.07 (0.72, 1.58)
Citalopram 7 0.6 27.9 0.93 (0.44, 1.97)
Paroxetine <5 0.6 30.0 0.90 (0.34, 2.42)
Sertraline 13 1.0 31.1 1.48 (0.85, 2.57)
Fluoxetine <5 0.5 37.0 0.83 (0.21, 3.35)
Escitalopram < 5 0.4 21.0 0.63 (0.09, 4.51)
Fluvoxamine 0 0.0
Male 13 50.0 33.3 326 53.3 27.0 0.88 (0.40, 1.92)
Preterm 18 69.2 25.8 493 80.6 24.9 0.54 (0.23, 1.28)
Any major birth defect 8 30.8 23.8 182 29.7 24.4 1.05 (0.45, 2.46)
Live birthsb 32 0.9 7.2 30.9 446 0.5 5.9 31.1 1.81 (1.26, 2.60)
Citalopram 7 0.6 1.7 29.7 1.28 (0.61, 2.72)
Paroxetine 7 1.0 8.1 33.4 2.18 (1.03, 4.61)
Sertraline 9 0.7 3.6 30.2 1.40 (0.72, 2.72)
Fluoxetine <5 1.1 5.2 26.8 2.30 (0.85, 6.19)
Escitalopram <5 1.6 0.2 34.3 3.52 (1.30, 9.49)
Fluvoxamine <5 2.1 6.5 37.5 4.52 (1.44, 14.24)
Male 18 56.3 8.9 29.6 238 53.4 6.0 30.6 1.12 (0.55, 2.31)
Preterm 20 62.5 7.3c 26.7 274 61.4 2.8 26.2 1.05 (0.50, 2.19)
Any major birth defect 6 18.8 2.6 28.3 138 30.9 6.7 32.3 0.52 (0.21, 1.28)
Most common cause of death codes:
P01 Fetus and newborn affected by
maternal complications of pregnancy
<5 0.1 24 0.0 2.10 (0.49, 8.87)
P07 Disorders related to short
gestation
and low birth weight, NEC
<5 0.1 14 0.0 7.19 (2.36, 21.85)
a One mother dispensed paroxetine and sertraline.
b One mother dispensed escitalopram and fluvoxamine; one mother dispensed citalopram and fluvoxamine.
c p< 0.05 in a t-test.
GA = gestational age; NEC = not elsewhere classified; OR =odds ratio; SSRI = selective serotonin reuptake inhibitor.
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1.1; 95% CI 0.7, 1.6). There were no differences
between the children with a major birth defect,
male children or the preterm births to adequately
describe this higher mortality risk. The codes
used to describe the deaths were reviewed. ‘P01
fetus and newborn affected by maternal compli-
cations of pregnancy’ and ‘P07 disorders related
to short gestation and low birth weight, not else-
where classified’ were the most common codes
used in the deaths of the children in the SSRI
group.
Death rates in the first year of life in children
live born were greater for each individual SSRI as
well as overall (table II). Although the number of
deaths is very small, a statistically significant in-
creased risk was seen in the children of mothers
dispensed paroxetine (OR 2.2; 95% CI 1.0, 4.6),
escitalopram (OR 3.5; 95% CI 1.3, 9.5) and flu-
voxamine (OR 4.5; 95% CI 1.4, 14.2). Two of the
three children in the fluvoxamine group had mo-
thers also dispensed escitalopram (N = 1) and ci-
talopram (N = 1).
There were no deaths in the SSRI group dur-
ing the second year of life.
Admissions in the First 2 Years of Life
A summary of the admissions for birth, in-
tensive care units (ICU) and non-birth admis-
sions is presented in table III. The mean LOS for
the birth admission was significantly longer in the
children in the SSRI group (5.2 vs 4.9 days; t-test:
0.0071); there were no other significantly differ-
ent LOS between the two groups. The children in
the SSRI group were also at a greater risk of a non-
birth admission or an ICU admission (ranging
from 31% to 48% increased risk) during the first
2 years of life.
Birth Admissions
Excluding the regular admission coded for a
birth (‘Z38 live born infants according to place of
birth’), the ten most common diagnoses recorded
on the birth admissions for term births of chil-
dren in the SSRI group are presented in table IV.
The most common diagnosis recorded was ‘Z03
medical observation and evaluation for suspected
diseases and conditions’ (OR 1.6; 95% CI 1.4,
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was ‘P22 respiratory distress of newborn’ (OR
1.7; 95%CI 1.5, 2.0) for 7.8% of all children in the
SSRI group versus 4.7% of all other children.
This is often seen in infants delivered by Caesar-
ean section; however, after adjusting for the type
of delivery there was still an increased risk (OR
1.7; 95% CI 1.5, 2.0). This was not seen in the
preterm births. Respiratory and cardiovascular
disorders specific to the perinatal period (P20-
P29) accounted for 13.8% of the diagnoses re-
ported on the birth admission for term births in
the SSRI group (OR 1.8; 95% CI 1.6, 2.0) versus
8.2% in the other children. The admissions, ‘P29.3
persistent fetal circulation, delayed closure of ductus
arteriosus, pulmonary hypertension of newborn
(persistent)’ comprised 0.2% (N = 8) of children in
the SSRI group and 0.1% (N = 86) of the non-
SSRI group term birth admissions (OR 2.4; 95%
CI 1.2, 5.0). After adjusting for Caesarean deliv-
ery, the risk of a child in the SSRI group born at
term with a diagnosis code of P29.3 being as-
signed remained at OR 2.4; 95% CI 1.2, 5.0.
The diagnosis for term births with the greatest
risk seen in the children in the SSRI group was
‘P96 other conditions originating in the perinatal
period’ (OR 3.9; 95% CI 3.3, 4.6). These codes






N % N % OR (95% CI)
Z03 Medical observation and evaluation for suspected diseases and conditions 430 13.0 7540 8.8 1.56 (1.41, 1.73)
P22 Respiratory distress of newborn 255 7.7 3986 4.6 1.73 (1.51, 1.97)
Adjusted for Caesarean delivery 1.71 (1.50, 1.96)
P92 Feeding problems of newborn 217 6.6 4881 5.7 1.17 (1.02, 1.35)
Z29 Need for other prophylactic measures 162 4.9 2985 3.5 1.44 (1.22, 1.69)
P96 Other conditions originating in the perinatal period 157 4.8 1086 1.3 3.91 (3.30, 4.65)
P39 Other infections specific to the perinatal period 151 4.6 3668 4.3 1.08 (0.91, 1.27)
P28 Other respiratory conditions originating in the perinatal period 147 4.5 2099 2.4 1.87 (1.57, 2.22)
P59 Neonatal jaundice from other and unspecified causes 139 4.2 4604 5.3 0.78 (0.66, 0.93)
P05 Slow fetal growth and fetal malnutrition 78 2.4 1356 1.6 1.51 (1.20, 1.91)
P70 Transitory disorders of carbohydrate metabolism specific to fetus and newborn 78 2.4 1322 1.5 1.55 (1.23, 1.96)
P20-P29 Respiratory and cardiovascular disorders specific to the perinatal period 455 13.8 7049 8.2 1.80 (1.62, 1.99)
Adjusted for Caesarean delivery 1.79 (1.62, 1.99)
P20 Intrauterine hypoxia 17 0.5 294 0.3 1.51 (0.93, 2.47)
P21 Birth asphyxia 32 1.0 382 0.4 2.20 (1.53, 3.16)
P22 Respiratory distress of newborn 255 7.7 3986 4.6 1.73 (1.51, 1.97)
P24 Neonatal aspiration syndromes 15 0.5 228 0.3 1.72 (1.02, 2.91)
P25 Air leak syndrome originating in the perinatal period 6 0.2 134 0.2 1.17 (0.52, 2.65)
P28 Other respiratory conditions originating in the perinatal period 147 4.5 2099 2.4 1.87 (1.57, 2.22)
P29 Cardiovascular disorders originating in the perinatal period 47 1.4 652 0.8 1.90 (1.41, 2.55)
Adjusted for Caesarean delivery 1.89 (1.40, 2.54)
P29.3 Persistent fetal circulation 8 0.2 86 0.1 2.43 (1.18, 5.03)
Adjusted for Caesarean delivery 2.42 (1.17, 4.99)
P96 Other conditions originating in the perinatal period 157 4.8 1086 1.3 3.91 (3.30, 4.65)
P96.1 Neonatal withdrawal symptoms from maternal use of drugs of addiction 40 1.2 206 0.2 5.12 (3.64, 7.20)
P96.2 Withdrawal symptoms from therapeutic use of drugs in newborn 8 0.2 8 0.0 26.18 (9.82, 69.80)
P96.8 Other specified conditions originating in the perinatal period 108 3.3 837 1.0 3.45 (2.82, 4.23)
OR = odds ratio; SSRI = selective serotonin reuptake inhibitor.
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were ‘P96.1 neonatal withdrawal symptoms from
maternal use of drugs of addiction’ (OR 5.1; 95%
CI 3.6, 7.2), ‘P96.2 withdrawal symptoms from
therapeutic use of drugs in newborn’ (OR 26.2;
95% CI 9.8, 69.8) and ‘P96.8 other specified
conditions originating in the perinatal period’
(OR 3.4; 95% CI 2.8, 4.2).
Non-Birth Admissions Up to 2 Years
Children born to a mother dispensed an SSRI
during her pregnancy were more likely to be ad-
mitted to an ICU during the first year of life (OR
1.4; 95% CI 1.3, 1.6) and also in the second year
of life (OR 1.3; 95% CI 1.1, 1.6) [table III]. There
was no difference in the LOS in ICU. Before the
age of 1 year, 32.8% of the children in the SSRI
group were admitted to hospital after the birth
admission, compared with 24.8% of the non-SSRI
group (OR 1.5; 95% CI 1.4, 1.6). The most com-
mon principal diagnosis was ‘J21 acute bronch-
iolitis’ (OR 1.6; 95% CI 1.3, 1.8) for 5.9% of all
children in the SSRI group versus 3.8% of all
other children (table V) and this remained a
higher risk when analysing just the non-smokers
(OR 1.7; 95% CI 1.4, 2.0). The risk of admission
was greater in the SSRI group for eight of the ten
most common diagnoses. The admissions were
also analysed separately for children of mothers
who had smoked or not smoked during the
pregnancy, as 28.6% of the mothers in the SSRI
group had smoked during their pregnancy com-
pared with 17.2% of the other mothers. Within
the non-smoking group of mothers, the risk of ad-
mission increased for all of the ten most common
Table V. Leading ten principal diagnosis codes for children in the selective serotonin reuptake inhibitor group and born at term, non-birth











N % N % OR (95% CI) OR (95% CI) OR (95% CI)
Children live born 2002–4 2797 69 125
Mother smoked during pregnancy 800 28.6 11 900 17.2
Children with a non-birth admission
£2 years
1200 42.9 23 576 34.1 1.45 (1.34, 1.57) 1.44 (1.31, 1.58) 1.35 (1.17, 1.56)
Mother smoked during pregnancy 369 46.1 4 619 38.8 1.35 (1.17, 1.56)
Non-smokers 831 41.6 18 957 33.1 1.44 (1.31, 1.58)
Principal diagnosis
J21 Acute bronchiolitis 164 5.9 2 645 3.8 1.57 (1.33, 1.84) 1.67 (1.37, 2.04) 1.11 (0.84, 1.46)
Z76 Persons encountering health
services in other circumstances
150 5.4 2 490 3.6 1.52 (1.28, 1.80) 1.59 (1.30, 1.94) 1.20 (0.88, 1.64)
G47 Sleep disorders 95 3.4 1 527 2.2 1.56 (1.26, 1.92) 1.64 (1.30, 2.07) 1.92 (1.14, 3.25)
H65 Nonsuppurative otitis media 84 3.0 1 276 1.8 1.65 (1.32, 2.06) 1.67 (1.30, 2.16) 1.92 (1.18, 3.11)
J06 Acute upper respiratory
infections of multiple and unspecified
sites
73 2.6 1 332 1.9 1.36 (1.07, 1.73) 1.45 (1.08, 1.93) 1.01 (0.66, 1.54)
R68 Other general symptoms and
signs
64 2.3 945 1.4 1.69 (1.31, 2.18) 1.83 (1.39, 2.41) 1.87 (0.93, 3.75)
A09 Diarrhoea and gastroenteritis of
presumed infectious origin
61 2.2 1 341 1.9 1.13 (0.87, 1.46) 1.24 (0.91, 1.70) 0.76 (0.48, 1.22)
B34 Viral infection of unspecified site 59 2.1 1 127 1.6 1.30 (1.00, 1.69) 1.29 (0.94, 1.77) 1.22 (0.76, 1.96)
P07 Disorders related to short
gestation and low birth weight, not
elsewhere classified
59 2.1 851 1.2 1.73 (1.32, 2.26) 1.37 (0.96, 1.97) 2.26 (1.50, 3.41)
A08 Viral and other specified
intestinal infections
48 1.7 805 1.2 1.48 (1.10, 1.99) 1.50 (1.06, 2.14) 1.30 (0.76, 2.22)
OR = odds ratio; SSRI = selective serotonin reuptake inhibitor.
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diagnoses and was statistically significant for
seven out of the ten most common diagnoses in
the children of the women in the SSRI group. In
the smoking group, the risk of admission re-
mained statistically significantly greater for three
of the ten diagnoses.
Additional Diagnoses in Non-Birth Admissions
up to 2 Years
Additional diagnoses were recorded on 53.1%
of the non-birth admission records for the chil-
dren in the SSRI group compared with 49.7% of
the records for the non-SSRI group (OR 1.2: 95%
CI 1.0, 1.3) [table VI]. The most common diag-
nosis recorded for both groups of children was
‘E86 volume depletion’ (OR 1.3; 95%CI 1.1, 1.7).
‘E83 disorders of mineral metabolism’ was the
diagnosis recorded with the greatest risk of ad-
mission in the children in the SSRI group (OR
6.2; 95%CI 2.3, 16.5). ‘H65 nonsuppurative otitis
media’ was also an increased risk for the children
in the SSRI group (OR 1.8; 95% CI 1.3, 2.4).
Discussion
Antidepressants are dispensed to a large num-
ber of pregnant women and we have previously
published data on the dispensing patterns and the
characteristics of the WA women dispensed an
SSRI during their pregnancy.[13] It is important
to have follow-up information on the develop-
mental well-being of the children exposed to SSRIs
in utero. This is the first population-based study
in Australia to examine the early hospital admis-
sions of the children born to women dispensed an
SSRI during their pregnancy. In this cohort, an
SSRI was dispensed to 3703 (3.8%) pregnant
women with 3764 children in utero. It is also one
of the largest studies of pregnant women using
SSRIs to follow the children through to 2 years of
age to investigate morbidity and mortality.
Our study shows that children born to women
dispensed an SSRI during their pregnancy were
still more likely to be born preterm than children
born to women not dispensed an SSRI during
pregnancy after adjusting for any previous pre-
term births, whether the mother smoked during
her pregnancy, SEIFA, parity and maternal age.
Their mean birth weight was 100 g less than the
mean weight of children in the non-SSRI group.
Following the birth admission and before the age
of 2 years, the children in the SSRI group were
more likely to be admitted for bronchiolitis,
which remained a significant risk for admission
after stratifying by whether the mother smoked
during her pregnancy. The mothers who smoked
during their pregnancy probably continued to
smoke around their child in the home. However,






N % N % OR (95% CI)
Children with a non-birth admission £2 years 1200 42.9 23 576 34.1 1.45 (1.34, 1.57)
Children with an additional diagnosis recorded 637 53.1 11 711 49.7 1.15 (1.02, 1.29)
E86 Volume depletion 83 3.0 1555 2.2 1.33 (1.06, 1.66)
B96 Other bacterial agents as the cause of diseases classified to other chapters 59 2.1 1000 1.4 1.47 (1.13, 1.91)
J06 Acute upper respiratory infections of multiple and unspecified sites 46 1.6 787 1.1 1.45 (1.08, 1.96)
P07 Disorders related to short gestation and low birth weight, not elsewhere classified 46 1.6 703 1.0 1.63 (1.20, 2.20)
R63 Symptoms and signs concerning food and fluid intake 43 1.5 803 1.2 1.33 (0.98, 1.81)
H66 Suppurative and unspecified otitis media 43 1.5 596 0.9 1.80 (1.31, 2.45)
K21 Gastro-oesophageal reflux disease 41 1.5 642 0.9 1.59 (1.15, 2.18)
R68 Other general symptoms and signs 40 1.4 680 1.0 1.46 (1.06, 2.01)
P92 Feeding problems of newborn 39 1.4 612 0.9 1.58 (1.14, 2.19)
B95 Streptococcus and Staphylococcus as the cause of diseases classified to other
chapters
38 1.4 632 0.9 1.49 (1.07, 2.08)
OR = odds ratio; SSRI = selective serotonin reuptake inhibitor.
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the mothers who didn’t smoke during their
pregnancy had a higher risk of their child being
admitted for bronchiolitis than the mothers who
did smoke (OR 1.7; 95% CI 1.4, 2.0 vs OR 1.1;
95% CI 0.8, 1.5) when compared with the non-
SSRI mothers. The next more likely admission
was for ‘persons encountering health services
in other circumstances’ – a category usually as-
signed when a healthy child is admitted due to
family circumstances. These admissions may be
related to the underlying depressive condition
of the mother and her ability to cope with a
newborn.
The main limitation of using dispensing data
relates to whether the medicine was consumed, or
consumed as directed, and we have no informa-
tion in this study for either of these aspects of use.
It is not known whether the mother actually in-
gested the medicine but by reviewing the repeat
dispensing of SSRIs throughout the trimesters of
pregnancy, adherence to the medicines may be
inferred. 75.4% of the women were dispensed an
SSRI in at least two consecutive trimesters, from
T0 to T3,[13] and this would indicate the women
are using the SSRIs as each dispensing costs from
$A3.60 to $A4.60 per medicine for concessional
patients and from $A22.40 to $A28.60 for general
patients, during the period of the study. The
mean number of dispenses was 2.2 in T1 and 4.4
overall. If the depression per se is the reason for
the increased risks and women with depression
are not treated with SSRIs or treated with non-
SSRI medicines, the effects observed in our study
would be understated as those women would be
in the non-SSRI group. Whilst the study is based
upon births in WA from 2002 to 2005, the SSRI
medications analysed are still the most commonly
prescribed SSRIs given to pregnant women. Al-
though the use of administrative data may not
provide a complete picture of the factors asso-
ciated with the use of medications in pregnancy,
the approach provides a rich source of informa-
tion on pregnancy outcomes in large populations.
A review of perinatal depression concluded that,
although limited, the available research suggests
that depression is one of the most common peri-
natal complications.[27] Since 2006, the American
College of Obstetricians and Gynecologists has
recommended screening for depression during each
trimester of pregnancy.[28] The first Australian
Clinical Practice Guidelines surrounding the de-
tection, management and treatment of perinatal
mental health disorders were established in
2011.[29] Australian studies have also highlighted
the need for screening pregnant women.[30,31] The
risks of allowing a depressive episode to remain
untreated may be far greater than those associated
with antidepressant treatment.[3] Depression may
increase the risk of self-injurious or suicidal be-
haviours in the mother but also may contribute to
inadequate self-care and poor compliance with
prenatal care.[32] Women with depression often
present with decreased appetite and consequently
lower-than-expected weight gain in pregnancy,
factors that have been associated with negative
pregnancy outcomes.[32,33] In addition, persons
with a major depressive disorder are twice as
likely to smoke as other persons[34-36] and to use
either alcohol or illicit drugs,[33] behaviours that
further increase risk to the foetus.[37] Although it
has been difficult to assess the impact of antena-
tal depression on foetal development and neona-
tal well-being in humans, several studies have
found an association between maternal depression
and factors that predict poor neonatal outcome,
including preterm birth, lower birth weight, smaller
head circumference and lower APGAR scores.[37-43]
A recent study by Ponder et al.[44] found that
maternal depression/anxiety affected a particular
gene expression in the placenta suggesting a pos-
sible mechanism for the effects of maternal mood
on foetal neurodevelopmental programming.
Studies have shown that SSRIs readily cross the
placenta,[6] are present in amniotic fluid[7] and
newborns exposed to them in utero may experi-
ence withdrawal-like symptoms after birth.[8,9]
The FDA have issued a Drug Safety Com-
munication (14 December 2011) related to the use
of SSRIs during pregnancy and the potential risk
of a rare heart and lung condition known as per-
sistent pulmonary hypertension of the newborn
(PPHN).[45] The initial Public Health Advisory
in July 2006 on this potential risk was based on
a single published study.[46] Since then, there
have been conflicting findings from new studies
evaluating this potential risk, making it unclear
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whether use of SSRIs during pregnancy can cause
PPHN. Two studies suggest an increased risk
for PPHN with SSRI use in pregnancy[46,47] and
three studies reported no increase in risk of
PPHN.[48-50] The FDA has reviewed the addi-
tional new study results and has concluded that,
given the conflicting results from different stud-
ies, it is premature to reach any conclusion about
a possible link between SSRI use in pregnancy
and PPHN. It was noted by the FDA commu-
nication that PPHN typically presents in term
or late-preterm births, and that Caesarean deliv-
ery was a potentially important factor. These
admissions would most likely have been coded
in our data as ‘P29.3 persistent fetal circula-
tion, delayed closure of ductus arteriosus, pul-
monary hypertension of newborn (persistent)’.
In term births, our study had 8 children in the
SSRI group and 86 in the non-SSRI group with
this as the principal diagnosis or as an addi-
tional diagnosis recorded on their birth ad-
mission (OR 2.4; 95%CI 1.2, 5.0). After adjusting
for Caesarean delivery, the risk did not change.
A very large population-based study in five
Nordic countries of births from 1996 to 2007 has
been published since the FDA communication.
They reported 33 children in the SSRI group
with PPHN with an unadjusted OR of 2.5; 95%
CI 1.8, 3.6.[51] The absolute risk of PPHN is still
low, and the P29.3 code also includes patent
ductus arteriosus.
Conclusion
Separating the effects of SSRI treatment from
the effects of the depression alone in the mothers
is an area for further research. The main limita-
tion of this study is that we can only use the dis-
pensing of an SSRI as a marker for depression
and anxiety in the mother.
Assessing the impact of antenatal depression
on the foetus, as well as the mother, requires a
balance of risks and benefits in the use of SSRIs.
Clinicians may need to counsel their patients re-
garding drinking habits, smoking, weight gain
and other factors that are known to increase the
risks of poor neonatal outcomes, especially those
factors that increase the risk of preterm birth.
We found ‘P20-P29 respiratory and cardio-
vascular disorders specific to the perinatal period’
accounted for 13.8% of the diagnoses reported on
the birth admission for term births in the SSRI
group (OR 1.8; 95% CI 1.6, 2.0) with more than
half of these coded as ‘P22 respiratory distress of
newborn’. We did not find a similar increase in
the preterm births.After adjusting for Caesarean
delivery, in infants exposed to SSRIs in preg-
nancy compared with non-exposed infants, there
was an increased risk of being assigned a diagnosis
code of P29.3 (PPHN) [OR 2.4; 95% CI 1.2, 5.0].
The increased risk of death in the first year of
life in the children in the SSRI group is a new
finding (OR 1.8; 95% CI 1.3, 2.6), although it is
based upon very small numbers. Of the SSRIs
used as monotherapy, paroxetine had the highest
risk of death in live birth infants (OR 2.2; 95% CI
1.0, 4.6) The categorization code for death ‘P01
fetus and newborn affected by maternal compli-
cations of pregnancy’ did not reach statistical
significance (OR 2.1; 95% CI 0.5, 8.9) but it is
interesting that this is twice as likely to be the most
common code used for death in the SSRI group
compared with the non-SSRI group. Nearly
every finding of a risk increase, if not extremely
strong, should only be regarded as a tentative signal
to be tested in independent studies.[52] Further
work is needed to investigate whether these in-
creased risks in mortality and morbidity are due
to prenatal exposure to SSRIs, to the maternal
depression itself, to SSRI use being a proxy for an
environmental exposure such as smoking or to a
combination of these factors. The dilemma for
researchers is in designing a study that can ac-
count for these and other confounders, as a ran-
domized clinical trial is not possible. In the
meantime, the clinician and the woman herself
need to balance the degree of severity of the de-
pressive disorder and the risk of relapse, with the
emerging safety profile of the individual SSRI.
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